Drug intelligence / Profile preview

Taponoto

Development stage: Unknown
Lead developer: TEOFARMA
Modality: Small Molecules
Administration: Otic

Overview

Taponoto is a topical ceruminolytic ear solution developed by Teofarma for the treatment of ear canal occlusion due to cerumen (earwax) buildup. It is a combination product containing potassium carbonate, glycerol, ethyl alcohol, and thymol. The mechanism of action is primarily physical and chemical: glycerol acts as an emollient to soften the earwax plug, while potassium carbonate facilitates its mobilization and eventual removal, typically through subsequent irrigation with water. It is marketed in several countries, including Spain, under the brand name Taponoto Neo.

Brand names: TaponotoTaponoto Neo

Beyond the preview

Go deeper on Taponoto.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Taponoto.

Explore the full profile